According to DRG epidemiology, more than 35 million people in the United States suffer from migraines. Despite being unde...
The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic...
The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a...
Recent European approval of three anti-CGRP-targeted MAbs—Aimovig (Novartis), Ajovy (Teva) and Emgality (Eli Lilly)—together with the expected...
Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States...
Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in...
Market Outlook According to DRG epidemiology, more than 35 million people in the United States suffer from migraines. Despite being unde...
Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States...
Coming December 2018 Market Outlook The migraine prophylaxis market stands poised for disruption following the launch of three anti-CGR...
The migraine market is comprised of an array of prescription acute and prophylactic treatments. Today, oral triptan products—the gold standard of...
Market Outlook With four anti-CGRP-targeted MAbs (e.g., Amgen/Novartis&rsqu...
DRG Epidemiology’s coverage of fibromyalgia comprises epidemiological estimates of key patient populations in the major mature pharmaceuti...
Market Outlook The migraine prophylaxis market stands poised for disruption with the launch of Amgen/Novartis’s Aimovig (erenumab) in May 2018...
The triptan drug class dominates the market for approved prescription acute treatments for migraine. Despite the array of approved triptan options,...
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence...
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the...
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the...
According to DRG epidemiology, more than 33 million people in the EU5 suffer from migraines an...
Get content updates to your inbox
Subscribe